CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas
mostafa, M., Awd, A., Elwan, A., ELSAYED, D., Hanafy, S. (2023). CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas. EKB Journal Management System, 29(6), 1497-1505. doi: 10.21608/zumj.2023.216665.2811
mona mostafa; Amr A. Awd; Amira Elwan; DALIA HAMOUDA ELSAYED; Sabah mohamed Hanafy. "CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas". EKB Journal Management System, 29, 6, 2023, 1497-1505. doi: 10.21608/zumj.2023.216665.2811
mostafa, M., Awd, A., Elwan, A., ELSAYED, D., Hanafy, S. (2023). 'CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas', EKB Journal Management System, 29(6), pp. 1497-1505. doi: 10.21608/zumj.2023.216665.2811
mostafa, M., Awd, A., Elwan, A., ELSAYED, D., Hanafy, S. CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas. EKB Journal Management System, 2023; 29(6): 1497-1505. doi: 10.21608/zumj.2023.216665.2811

CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas

Zagazig University Medical Journal
Volume 29, Issue 6, November and December 2023, Page 1497-1505  XML PDF (570.97 K)
Document Type: Original Article
DOI: 10.21608/zumj.2023.216665.2811
View on SCiNiTO View on SCiNiTO
Authors
mona mostafa email orcid 1; Amr A. Awd2; Amira Elwan3; DALIA HAMOUDA ELSAYED4; Sabah mohamed Hanafy5
1Zagazig university
2Obstetrics and Gynecology , Faculty of medicine, Zagazig University
3Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Egypt
4MEDICAL ONCOLOGY FACULTY OF MEDICINE ZAGAZIG UNIVERSITY
5pathology department
Abstract
BACKGROUND: The basis of cancer management is understanding its underlying molecular abnormalities. To improve survival of ovarian cancer patients, new therapeutic targets and prognostic markers are needed. SMYD3 and CDK9 are two markers that play important role in epigenetic regulation and promotion of oncogenic process. They have to be under investigation to be used as target for therapy. Objective: evaluation the diagnostic and prognostic value of the immunohistochemical expression of SMYD3 and CDK9 in serous ovarian carcinoma (SOC). Methods: 50 cases of SOC and 50 benign ovarian lesions cases were included in this study. The morphological classification was assessed according to the World Health Organization criteria. Immunohistochemistry (IHC) for CDK9 and SMYD3 was performed. Results: SMYD3 and CDK9 was highly expressed in cancer compared with benign lesions (p <0.001 and <0.05 respectively). High CDK9 and SMYD3 expression were significantly associated with vascular invasion and advanced stage disease (p <0.001 for both). Patients who exhibited high SMYD3 and CKD9 expression showed poor treatment response, drug resistance and higher frequency of relapse and mortality. Conclusions: The immunohistochemical staining of SMYD3 and CDK9 is higher in serous ovarian carcinoma compared with benign ovarian lesions and represents a worse prognostic factor.
Keywords
SMYD3; CDK9; serous ovarian carcinomas; prognosis; immunohistochemistry
Statistics
Article View: 115
PDF Download: 58